FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a method for treating multiple myeloma in a subject using an antibody to CD38. Also a composition for treatment of multiple myeloma, a kit for treating multiple myeloma in a subject with an antibody to CD38, a combination for treating multiple myeloma in a subject with an antibody to CD38 are disclosed.
EFFECT: invention has the ability to treat effectively multiple myeloma in a subject using an antibody to CD38.
46 cl, 3 ex, 1 tbl, 22 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| FORMULATIONS BASED ON ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | 2020 |
|
RU2838165C1 |
| HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
| METHODS OF TREATING MULTIPLE MYELOMA | 2020 |
|
RU2838203C2 |
| AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
| DIAGNOSING AND TREATING MALIGNANT TUMOUR WITH USING ANTI-EREG ANTIBODY | 2007 |
|
RU2537245C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
